America's obesity rate just started falling
For twenty-five years the number only moved one direction. Then a Gallup report out this July showed the US adult obesity rate dropping to 36.4%, down from a peak of 39.9% in 2022 78.
Over that same stretch, the share of adults who say they're currently taking a GLP-1 drug for weight loss jumped from 3% in 2024 to 11% in 2026, roughly 29 million people 78. Nobody can yet prove the drugs caused the whole shift, but the timing is hard to ignore. Cambridge researchers, meanwhile, worked out something that had puzzled the field: some obesity drugs work by switching a brain receptor called GIPR on, others by switching it off, and both cause weight loss. In mice, activating GIPR in the brainstem cut appetite, while blocking the same receptor in the hypothalamus released a kind of brake on fullness signals, a different mechanism arriving at the same result 3. Combine the two approaches with an existing GLP-1 drug and the effect gets stronger still.
What each field noticed (2)
Natural Sci.
The Cambridge team cared about the wiring: why Mounjaro and Zepbound, which activate GIPR, and MariTide, which blocks it, both work. The answer lives in which brain region gets touched, not whether the receptor is turned up or down 3.

Ozempic is not just a weight-loss story anymore
Vox's Future Perfect looked at the twenty-five-year backdrop: menu calorie counts, soda taxes, wellness programs, none of which bent the curve, then a molecule that, almost by accident, did 78.
Read the story